Article
Analysis of hepatitis C virus resistance to silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4B.
Hepatology (Baltimore, Md.) - 1 Mar 2013
Esser-Nobis Katharina, Romero-Brey Inés, Ganten Tom M, Gouttenoire Jérôme, Harak Christian, Klein Rahel, Schemmer Peter, Binder Marco, Schnitzler Paul, Moradpour Darius, Bartenschlager Ralf, Polyak Stephen J, Stremmel Wolfgang, Penin François, Eisenbach Christoph, Lohmann Volker
Abstract excerpt
UNLABELLED: Intravenous silibinin (SIL) is an approved therapeutic that has recently been applied to patients with chronic hepatitis C, successfully clearing hepatitis C virus (HCV) infection in some patients even in monotherapy. Previous studies suggested multiple antiviral mechanisms of SIL; however, the dominant mode of action has not been determined. We first analyzed the impact of SIL on replication of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
